CLAIM #37022 · Eli Lilly and Company (LLY) · 2025Q2 earnings call · Aug 7, 2025 · due Dec 31, 2025
“We expect the modified dosing regimen to be part of the EU labeling at launch as well.”
Dr. Dan Skovronsky · Chief Scientific Officer
PENDING
graded after results covering Dec 31, 2025 are reported
Verify independently
SEC filings for LLY ↗ · Claim quote is verbatim from the 2025Q2 earnings call.